Eintrag weiter verarbeiten
Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents
Gespeichert in:
| Zeitschriftentitel: | Blood |
|---|---|
| Personen und Körperschaften: | , , |
| In: | Blood, 131, 2018, 16, S. 1777-1789 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Hematology
|
| Schlagwörter: |
| author_facet |
Xu, Xiaohong Ruby Yousef, George M. Ni, Heyu Xu, Xiaohong Ruby Yousef, George M. Ni, Heyu |
|---|---|
| author |
Xu, Xiaohong Ruby Yousef, George M. Ni, Heyu |
| spellingShingle |
Xu, Xiaohong Ruby Yousef, George M. Ni, Heyu Blood Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents Cell Biology Hematology Immunology Biochemistry |
| author_sort |
xu, xiaohong ruby |
| spelling |
Xu, Xiaohong Ruby Yousef, George M. Ni, Heyu 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2017-05-743187 <jats:title>Abstract</jats:title> <jats:p>Platelets have long been recognized as key players in hemostasis and thrombosis; however, growing evidence suggests that they are also significantly involved in cancer, the second leading cause of mortality worldwide. Preclinical and clinical studies showed that tumorigenesis and metastasis can be promoted by platelets through a wide variety of crosstalk between platelets and cancer cells. For example, cancer changes platelet behavior by directly inducing tumor-platelet aggregates, triggering platelet granule and extracellular vesicle release, altering platelet phenotype and platelet RNA profiles, and enhancing thrombopoiesis. Reciprocally, platelets reinforce tumor growth with proliferation signals, antiapoptotic effect, and angiogenic factors. Platelets also activate tumor invasion and sustain metastasis via inducing an invasive epithelial-mesenchymal transition phenotype of tumor cells, promoting tumor survival in circulation, tumor arrest at the endothelium, and extravasation. Furthermore, platelets assist tumors in evading immune destruction. Hence, cancer cells and platelets maintain a complex, bidirectional communication. Recently, aspirin (acetylsalicylic acid) has been recognized as a promising cancer-preventive agent. It is recommended at daily low dose by the US Preventive Services Task Force for primary prevention of colorectal cancer. The exact mechanisms of action of aspirin in chemoprevention are not very clear, but evidence has emerged that suggests a platelet-mediated effect. In this article, we will introduce how cancer changes platelets to be more cancer-friendly and highlight advances in the modes of action for aspirin in cancer prevention. We also discuss the opportunities, challenges, and opposing viewpoints on applying aspirin and other antiplatelet agents for cancer prevention and treatment.</jats:p> Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents Blood |
| doi_str_mv |
10.1182/blood-2017-05-743187 |
| facet_avail |
Online Free |
| finc_class_facet |
Chemie und Pharmazie Biologie Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDE3LTA1LTc0MzE4Nw |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDE3LTA1LTc0MzE4Nw |
| institution |
DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 DE-105 DE-14 |
| imprint |
American Society of Hematology, 2018 |
| imprint_str_mv |
American Society of Hematology, 2018 |
| issn |
0006-4971 1528-0020 |
| issn_str_mv |
0006-4971 1528-0020 |
| language |
English |
| mega_collection |
American Society of Hematology (CrossRef) |
| match_str |
xu2018cancerandplateletcrosstalkopportunitiesandchallengesforaspirinandotherantiplateletagents |
| publishDateSort |
2018 |
| publisher |
American Society of Hematology |
| recordtype |
ai |
| record_format |
ai |
| series |
Blood |
| source_id |
49 |
| title |
Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents |
| title_unstemmed |
Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents |
| title_full |
Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents |
| title_fullStr |
Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents |
| title_full_unstemmed |
Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents |
| title_short |
Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents |
| title_sort |
cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents |
| topic |
Cell Biology Hematology Immunology Biochemistry |
| url |
http://dx.doi.org/10.1182/blood-2017-05-743187 |
| publishDate |
2018 |
| physical |
1777-1789 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>Platelets have long been recognized as key players in hemostasis and thrombosis; however, growing evidence suggests that they are also significantly involved in cancer, the second leading cause of mortality worldwide. Preclinical and clinical studies showed that tumorigenesis and metastasis can be promoted by platelets through a wide variety of crosstalk between platelets and cancer cells. For example, cancer changes platelet behavior by directly inducing tumor-platelet aggregates, triggering platelet granule and extracellular vesicle release, altering platelet phenotype and platelet RNA profiles, and enhancing thrombopoiesis. Reciprocally, platelets reinforce tumor growth with proliferation signals, antiapoptotic effect, and angiogenic factors. Platelets also activate tumor invasion and sustain metastasis via inducing an invasive epithelial-mesenchymal transition phenotype of tumor cells, promoting tumor survival in circulation, tumor arrest at the endothelium, and extravasation. Furthermore, platelets assist tumors in evading immune destruction. Hence, cancer cells and platelets maintain a complex, bidirectional communication. Recently, aspirin (acetylsalicylic acid) has been recognized as a promising cancer-preventive agent. It is recommended at daily low dose by the US Preventive Services Task Force for primary prevention of colorectal cancer. The exact mechanisms of action of aspirin in chemoprevention are not very clear, but evidence has emerged that suggests a platelet-mediated effect. In this article, we will introduce how cancer changes platelets to be more cancer-friendly and highlight advances in the modes of action for aspirin in cancer prevention. We also discuss the opportunities, challenges, and opposing viewpoints on applying aspirin and other antiplatelet agents for cancer prevention and treatment.</jats:p> |
| container_issue |
16 |
| container_start_page |
1777 |
| container_title |
Blood |
| container_volume |
131 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792345139258064905 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:18:44.427Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Cancer+and+platelet+crosstalk%3A+opportunities+and+challenges+for+aspirin+and+other+antiplatelet+agents&rft.date=2018-04-19&genre=article&issn=1528-0020&volume=131&issue=16&spage=1777&epage=1789&pages=1777-1789&jtitle=Blood&atitle=Cancer+and+platelet+crosstalk%3A+opportunities+and+challenges+for+aspirin+and+other+antiplatelet+agents&aulast=Ni&aufirst=Heyu&rft_id=info%3Adoi%2F10.1182%2Fblood-2017-05-743187&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792345139258064905 |
| author | Xu, Xiaohong Ruby, Yousef, George M., Ni, Heyu |
| author_facet | Xu, Xiaohong Ruby, Yousef, George M., Ni, Heyu, Xu, Xiaohong Ruby, Yousef, George M., Ni, Heyu |
| author_sort | xu, xiaohong ruby |
| container_issue | 16 |
| container_start_page | 1777 |
| container_title | Blood |
| container_volume | 131 |
| description | <jats:title>Abstract</jats:title> <jats:p>Platelets have long been recognized as key players in hemostasis and thrombosis; however, growing evidence suggests that they are also significantly involved in cancer, the second leading cause of mortality worldwide. Preclinical and clinical studies showed that tumorigenesis and metastasis can be promoted by platelets through a wide variety of crosstalk between platelets and cancer cells. For example, cancer changes platelet behavior by directly inducing tumor-platelet aggregates, triggering platelet granule and extracellular vesicle release, altering platelet phenotype and platelet RNA profiles, and enhancing thrombopoiesis. Reciprocally, platelets reinforce tumor growth with proliferation signals, antiapoptotic effect, and angiogenic factors. Platelets also activate tumor invasion and sustain metastasis via inducing an invasive epithelial-mesenchymal transition phenotype of tumor cells, promoting tumor survival in circulation, tumor arrest at the endothelium, and extravasation. Furthermore, platelets assist tumors in evading immune destruction. Hence, cancer cells and platelets maintain a complex, bidirectional communication. Recently, aspirin (acetylsalicylic acid) has been recognized as a promising cancer-preventive agent. It is recommended at daily low dose by the US Preventive Services Task Force for primary prevention of colorectal cancer. The exact mechanisms of action of aspirin in chemoprevention are not very clear, but evidence has emerged that suggests a platelet-mediated effect. In this article, we will introduce how cancer changes platelets to be more cancer-friendly and highlight advances in the modes of action for aspirin in cancer prevention. We also discuss the opportunities, challenges, and opposing viewpoints on applying aspirin and other antiplatelet agents for cancer prevention and treatment.</jats:p> |
| doi_str_mv | 10.1182/blood-2017-05-743187 |
| facet_avail | Online, Free |
| finc_class_facet | Chemie und Pharmazie, Biologie, Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDE3LTA1LTc0MzE4Nw |
| imprint | American Society of Hematology, 2018 |
| imprint_str_mv | American Society of Hematology, 2018 |
| institution | DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14 |
| issn | 0006-4971, 1528-0020 |
| issn_str_mv | 0006-4971, 1528-0020 |
| language | English |
| last_indexed | 2024-03-01T17:18:44.427Z |
| match_str | xu2018cancerandplateletcrosstalkopportunitiesandchallengesforaspirinandotherantiplateletagents |
| mega_collection | American Society of Hematology (CrossRef) |
| physical | 1777-1789 |
| publishDate | 2018 |
| publishDateSort | 2018 |
| publisher | American Society of Hematology |
| record_format | ai |
| recordtype | ai |
| series | Blood |
| source_id | 49 |
| spelling | Xu, Xiaohong Ruby Yousef, George M. Ni, Heyu 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2017-05-743187 <jats:title>Abstract</jats:title> <jats:p>Platelets have long been recognized as key players in hemostasis and thrombosis; however, growing evidence suggests that they are also significantly involved in cancer, the second leading cause of mortality worldwide. Preclinical and clinical studies showed that tumorigenesis and metastasis can be promoted by platelets through a wide variety of crosstalk between platelets and cancer cells. For example, cancer changes platelet behavior by directly inducing tumor-platelet aggregates, triggering platelet granule and extracellular vesicle release, altering platelet phenotype and platelet RNA profiles, and enhancing thrombopoiesis. Reciprocally, platelets reinforce tumor growth with proliferation signals, antiapoptotic effect, and angiogenic factors. Platelets also activate tumor invasion and sustain metastasis via inducing an invasive epithelial-mesenchymal transition phenotype of tumor cells, promoting tumor survival in circulation, tumor arrest at the endothelium, and extravasation. Furthermore, platelets assist tumors in evading immune destruction. Hence, cancer cells and platelets maintain a complex, bidirectional communication. Recently, aspirin (acetylsalicylic acid) has been recognized as a promising cancer-preventive agent. It is recommended at daily low dose by the US Preventive Services Task Force for primary prevention of colorectal cancer. The exact mechanisms of action of aspirin in chemoprevention are not very clear, but evidence has emerged that suggests a platelet-mediated effect. In this article, we will introduce how cancer changes platelets to be more cancer-friendly and highlight advances in the modes of action for aspirin in cancer prevention. We also discuss the opportunities, challenges, and opposing viewpoints on applying aspirin and other antiplatelet agents for cancer prevention and treatment.</jats:p> Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents Blood |
| spellingShingle | Xu, Xiaohong Ruby, Yousef, George M., Ni, Heyu, Blood, Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents, Cell Biology, Hematology, Immunology, Biochemistry |
| title | Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents |
| title_full | Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents |
| title_fullStr | Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents |
| title_full_unstemmed | Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents |
| title_short | Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents |
| title_sort | cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents |
| title_unstemmed | Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents |
| topic | Cell Biology, Hematology, Immunology, Biochemistry |
| url | http://dx.doi.org/10.1182/blood-2017-05-743187 |